Multi-Kinase Inhibitor with or without Atezolizumab in Previously Treated Liver Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare the effectiveness of atezolizumab + a multi-kinase inhibitor (either cabozantinib or lenvatinib) versus a multi-kinase inhibitor alone.

What is the Condition Being Studied?

Hepatocellular Carcinoma

Who Can Participate in the Study?

Adults who:
- Have hepatocellular carcinoma (a type of liver cancer)
- Received exactly 1 previous line of therapy, which must have been atezolizumab + bevacizumab

For more information about who can join this study, please contact the study team at john.d.gibbs@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Take one of the study drugs, either cabozantinib or lenvatinib, by mouth once per day
- Receive the study drug atezolizumab through an IV once every 3 weeks (if assigned)
- Return to the clinic every 3 weeks so we can monitor your health
- Give blood and urine for testing
- Get CT or MRI scans every 9 weeks

You may be on the study drugs for up to 2 years.

Study Details

Full Title
A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab (ACCRU-2008)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00110227
NCT: NCT05168163
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698